.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Citi
AstraZeneca
Cantor Fitzgerald
McKinsey
Daiichi Sankyo
US Army
Medtronic
Fuji
Cipla
Farmers Insurance

Generated: December 17, 2017

DrugPatentWatch Database Preview

ADZENYS XR-ODT Drug Profile

« Back to Dashboard

When do Adzenys Xr-odt patents expire, and what generic alternatives are available?

Adzenys Xr-odt is a drug marketed by Neos Theraps and is included in one NDA. There are four patents protecting this drug.

This drug has two patent family members in two countries.

The generic ingredient in ADZENYS XR-ODT is amphetamine. There are fifty-three drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the amphetamine profile page.

US Patents and Regulatory Information

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Neos TherapsADZENYS XR-ODTamphetamineTABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL204326-001Jan 27, 2016RXYesNo► Subscribe► SubscribeY► Subscribe
Neos TherapsADZENYS XR-ODTamphetamineTABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL204326-005Jan 27, 2016RXYesNo► Subscribe► SubscribeY► Subscribe
Neos TherapsADZENYS XR-ODTamphetamineTABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL204326-006Jan 27, 2016RXYesYes► Subscribe► SubscribeY► Subscribe
Neos TherapsADZENYS XR-ODTamphetamineTABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL204326-002Jan 27, 2016RXYesNo► Subscribe► SubscribeY► Subscribe
Neos TherapsADZENYS XR-ODTamphetamineTABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL204326-001Jan 27, 2016RXYesNo► Subscribe► SubscribeY► Subscribe
Neos TherapsADZENYS XR-ODTamphetamineTABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL204326-003Jan 27, 2016RXYesNo► Subscribe► SubscribeY► Subscribe
Neos TherapsADZENYS XR-ODTamphetamineTABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL204326-005Jan 27, 2016RXYesNo► Subscribe► SubscribeY► Subscribe
Neos TherapsADZENYS XR-ODTamphetamineTABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL204326-002Jan 27, 2016RXYesNo► Subscribe► SubscribeY► Subscribe
Neos TherapsADZENYS XR-ODTamphetamineTABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL204326-005Jan 27, 2016RXYesNo► Subscribe► SubscribeY► Subscribe
Neos TherapsADZENYS XR-ODTamphetamineTABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL204326-004Jan 27, 2016RXYesNo► Subscribe► SubscribeY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Tradename: ADZENYS XR-ODT

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,072,680Compositions comprising methylphenidate complexed with ion-exchange resin particles► Subscribe
9,089,496Compositions comprising methylphenidate complexed with ion-exchange resin particles► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: ADZENYS XR-ODT

Country Document Number Estimated Expiration
European Patent Office2726066► Subscribe
World Intellectual Property Organization (WIPO)2013003622► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

McKesson
Cerilliant
AstraZeneca
Daiichi Sankyo
Harvard Business School
Deloitte
US Department of Justice
UBS
Chinese Patent Office
Argus Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot